Avenzo Therapeutics
PrivateLast Round
Private Placement
Jun 1, 2026
Est. Valuation
$515M
Total Funding Raised
$792.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Avenzo Therapeutics is a biotechnology company that develops next-generation oncology therapies, including small-molecule inhibitors and antibody-drug conjugates, for patients with cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Avenzo Therapeutics Comparables
Compare Avenzo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Incyclix Bio | 86% | |
| NiKang Therapeutics | 81% | |
| Pyxa Pharmaceuticals | 80% | |
Avenzo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jun 1, 2026 | ||||
| Series B | Sep 22, 2025 | ||||
| Series A | Nov 18, 2024 | ||||
| Series A Extension | Mar 26, 2024 | ||||
| Series A | May 25, 2023 |
Key People
Founding team and executive leadership
Avenzo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Private Placement, Series A Extension, Series A, Series B |
| New Enterprise Associates (NEA) | Private Placement, Series B, Series A Extension, Series A |
| TF Capital | Series A Extension, Series A, Series B |
| 渶策资本 | Series A Extension, Series A, Series B |
| Deep Track Capital | Private Placement, Series B, Series A Extension, Series A |
| OrbiMed | Private Placement, Series A Extension, Series A, Series B |
| Foresite Capital | Private Placement, Series A Extension, Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 1, 2026
$215M round with participation from NEA and Blackstone.
- Dec 21, 2025
Acquired ex-Greater China rights for an asset for $50M upfront.
Avenzo Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Avenzo Therapeutics's valuation, stock price, and market status.